(LYEL) Lyell Immunopharma - Ratings and Ratios
T-Cell, Cancer, Therapy, Immunotherapy, Pipeline
LYEL EPS (Earnings per Share)
LYEL Revenue
Description: LYEL Lyell Immunopharma
Lyell Immunopharma Inc (NASDAQ:LYEL) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock is currently trading at $10.58.
The stocks moving averages indicate a mixed signal, with the short-term SMA20 at $11.25, suggesting a potential resistance level, while the SMA50 is at $10.36, indicating a possible support level. The long-term SMA200 is at $12.40, showing a significant deviation from the current price, potentially indicating a downtrend.
From a fundamental analysis perspective, Lyell Immunopharmas market capitalization is approximately $210.94 million, with a negative P/E ratio, indicating that the company is not profitable. The Return on Equity (RoE) is -73.66%, suggesting significant losses. Key economic drivers for the company include the development and commercialization of its biotechnology products, research and development expenses, and the overall demand for its products.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate should be closely monitored. Additionally, the companys pipeline progress, clinical trial results, and regulatory approvals will be crucial in determining its future prospects.
The biotechnology industry is highly competitive and subject to significant regulatory risks. Lyell Immunopharmas success will depend on its ability to develop innovative products, manage its finances effectively, and navigate the complex regulatory landscape.
LYEL Stock Overview
| Market Cap in USD | 219m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-06-17 |
LYEL Stock Ratings
| Growth Rating | -87.3% |
| Fundamental | 26.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -62.6% |
| Analyst Rating | 2.75 of 5 |
LYEL Dividends
Currently no dividends paidLYEL Growth Ratios
| Growth Correlation 3m | 80.6% |
| Growth Correlation 12m | -70.7% |
| Growth Correlation 5y | -95.4% |
| CAGR 5y | -56.39% |
| CAGR/Max DD 3y | -0.59 |
| CAGR/Mean DD 3y | -0.74 |
| Sharpe Ratio 12m | -1.09 |
| Alpha | 0.19 |
| Beta | 0.629 |
| Volatility | 81.91% |
| Current Volume | 158.4k |
| Average Volume 20d | 27.9k |
| Stop Loss | 11.4 (-7.4%) |
| Signal | -1.00 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-331.4m TTM) > 0 and > 6% of Revenue (6% = 3600 TTM) |
| FCFTA -0.42 (>2.0%) and ΔFCFTA -16.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 408.9k% (prev 868.4k%; Δ -459.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.44 (>3.0%) and CFO -171.5m > Net Income -331.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.8m) change vs 12m ago -94.21% (target <= -2.0% for YES) |
| Gross Margin -8277 % (prev -37.1k%; Δ 28.8kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.01% (prev 0.01%; Δ 0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -28.27
| (A) 0.64 = (Total Current Assets 282.2m - Total Current Liabilities 36.9m) / Total Assets 385.5m |
| (B) -3.74 = Retained Earnings (Balance) -1.44b / Total Assets 385.5m |
| warn (B) unusual magnitude: -3.74 — check mapping/units |
| (C) -0.42 = EBIT TTM -216.2m / Avg Total Assets 519.8m |
| (D) -16.64 = Book Value of Equity -1.44b / Total Liabilities 86.5m |
| Total Rating: -28.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.31
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.29 = 2.46 |
| 5. Debt/Ebitda -0.43 = -2.50 |
| 6. ROIC - WACC (= -63.17)% = -12.50 |
| 7. RoE -85.58% = -2.50 |
| 8. Rev. Trend -26.81% = -2.01 |
| 9. EPS Trend -52.69% = -2.63 |
What is the price of LYEL shares?
Over the past week, the price has changed by -5.81%, over one month by +13.09%, over three months by +26.91% and over the past year by -55.72%.
Is Lyell Immunopharma a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LYEL is around 7.27 USD . This means that LYEL is currently overvalued and has a potential downside of -40.94%.
Is LYEL a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the LYEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | -10.6% |
| Analysts Target Price | 11 | -10.6% |
| ValueRay Target Price | 8 | -34.8% |
Last update: 2025-09-04 04:42
LYEL Fundamental Data Overview
CCE Cash And Equivalents = 276.8m USD (Cash And Short Term Investments, last quarter)
P/S = 3653.3298
P/B = 0.7333
Beta = -0.198
Revenue TTM = 60.0k USD
EBIT TTM = -216.2m USD
EBITDA TTM = -200.0m USD
Long Term Debt = 49.6m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 36.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 86.5m USD (Calculated: Short Term 36.9m + Long Term 49.6m)
Net Debt = -52.2m USD (from netDebt column, last quarter)
Enterprise Value = 28.9m USD (219.2m + Debt 86.5m - CCE 276.8m)
Interest Coverage Ratio = unknown (Ebit TTM -216.2m / Interest Expense TTM 0.0)
FCF Yield = -562.7% (FCF TTM -162.9m / Enterprise Value 28.9m)
FCF Margin = -271.4k% (FCF TTM -162.9m / Revenue TTM 60.0k)
Net Margin = -552.3k% (Net Income TTM -331.4m / Revenue TTM 60.0k)
Gross Margin = -8277 % ((Revenue TTM 60.0k - Cost of Revenue TTM 5.03m) / Revenue TTM)
Tobins Q-Ratio = -0.02 (set to none) (Enterprise Value 28.9m / Book Value Of Equity -1.44b)
Interest Expense / Debt = 6.08% (Interest Expense 5.26m / Debt 86.5m)
Taxrate = 21.0% (US default)
NOPAT = -216.2m (EBIT -216.2m, no tax applied on loss)
Current Ratio = 7.65 (Total Current Assets 282.2m / Total Current Liabilities 36.9m)
Debt / Equity = 0.29 (Debt 86.5m / last Quarter total Stockholder Equity 298.9m)
Debt / EBITDA = -0.43 (Net Debt -52.2m / EBITDA -200.0m)
Debt / FCF = -0.53 (Debt 86.5m / FCF TTM -162.9m)
Total Stockholder Equity = 387.2m (last 4 quarters mean)
RoA = -85.98% (Net Income -331.4m, Total Assets 385.5m )
RoE = -85.58% (Net Income TTM -331.4m / Total Stockholder Equity 387.2m)
RoCE = -49.50% (Ebit -216.2m / (Equity 387.2m + L.T.Debt 49.6m))
RoIC = -55.84% (NOPAT -216.2m / Invested Capital 387.2m)
WACC = 7.33% (E(219.2m)/V(305.7m) * Re(8.33%)) + (D(86.5m)/V(305.7m) * Rd(6.08%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 66.67 | Cagr: -22.62%
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -162.9m)
EPS Correlation: -52.69 | EPS CAGR: -83.19% | SUE: -4.0 | # QB: 0
Revenue Correlation: -26.81 | Revenue CAGR: 42.86% | SUE: 0.60 | # QB: 0
Additional Sources for LYEL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle